Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria

• •The subject is at least 18 years of age.
• •The subject has histologically or cytology documented Stage IIIB with pleural effusion or Stage IV NSCLC. The subject must have measurable disease (RECIST Criteria for Tumor Response).
• •The subject has not received first line therapy for treatment of NSCLC.
• •The subject must not be pregnant or lactating and all subjects (male and female) must use a contraceptive method deemed acceptable by the investigator while in the study and for up to two months following completion of therapy.
• •The subject has an Eastern Cooperative Oncology Group (ECOG) performance score of 0-1.
• •The subject is able to self-administer or has a caregiver who can reliably administer SC injections.
• •The subject must have adequate bone marrow, renal and hepatic function as follows:
• •* Bone marrow: White blood cell count (WBC) \>= 3,000/mm3; Platelets; \>= 100,000/mm3; Hemoglobin \>= 9.0 g/dL;
• •* Renal function: Serum creatinine \<= 2.0 mg/dL;
• •* Hepatic function: Bilirubin \<= 1.5 mg/dL; AST and ALT \<= 1.5 X the upper normal limit (ULN); unless liver metastases are present, then AST and ALT \<= 5.0 x ULN.
• •The subject has voluntarily signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved consent prior to any study specific procedures.